IgA Antiphospholipid Antibodies in Antiphospholipid Syndrome and Systemic Lupus Erythematosus

Reshetnyak, T.; Cheldieva, Fariza; Cherkasova, M.; Лила, А. М.; Nasonov, E.

doi:10.3390/ijms23169432

Cited by 11 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have demonstrated a link between the IgA isotypes and thrombosis ( Pericleous et al, 2016 ; Tebo et al, 2016 ). Recently, Reshetnyak et al reported that IgA aCL and IgA aβ2GPI had a high specificity (95% and 93%) but a low sensitivity (54% and 44%) in detecting APS ( Reshetnyak et al, 2022 ). The diagnostic value of IgA aPL is worthy of further study in the future.…”

Section: Discussionmentioning

confidence: 99%

Research trends and frontiers on antiphospholipid syndrome: A 10-year bibliometric analysis (2012–2021)

Huang²,

Qi³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Objectives: A growing body of studies related to antiphospholipid syndrome (APS) have been published in recent years. Nevertheless, there is a lack of visualized and systematic analysis in the literature on APS. Hence, this study sought to conduct a bibliometric analysis to identify research status and discover frontiers in the field.Methods: Articles and reviews concerning APS were acquired from the Web of Science Core Collection (WoSCC) database. CiteSpace, VOSviewer and a bibliometric online analysis platform were employed to conduct a visualization and knowledge-map analysis.Results: A total of 1,390 publications regarding APS were identified. Globally, Italy contributed the most publications. The University of Padua was the most productive institution. Lupus ranked first in both the most published and most co-cited journals. Savino Sciascia and Spiros Miyakis were the most prolific and most co-cited authors, respectively. “Vitamin K antagonists (VKA)” and “immunoglobulin A (IgA)” were current research foci. Burst analysis of keywords suggested that “neutrophil extracellular trap (NET),” “direct oral anticoagulant (DOAC),” “open label,” “outcome,” “hydroxychloroquine (HCQ),” and “arterial thrombosis (AT)” were significant future research frontiers.Conclusion: The scientific literature on APS has increased steadily in the past 10 years. The clinical studies on the treatment and mechanism research of APS are recognized as promising research hotspots in the domain of APS. The research status and trends of APS publications from the bibliometric perspective can provide a practical guide and important reference for subsequent studies by researchers and physicians in the domain.

show abstract

Section: Discussionmentioning

confidence: 99%

Research trends and frontiers on antiphospholipid syndrome: A 10-year bibliometric analysis (2012–2021)

Huang²,

Qi³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Patients with primary APS and patients with secondary APS associated to SLE, have a higher prevalence and a higher level of IgA aCL and IgA anti-β 2GPI, when compared to patients with SLE or other autoimmune diseases and without APS. Moreover, these antibodies demonstrate an important correlation with thrombotic events [ 11 ]. aPLs positivity can worsen the prognosis of several diseases, which was well demonstrated by Ruaro and coll., who described a correlation between antiphospholipid antibody positivity and pulmonary embolism events in sarcoidosis patients [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Antiphospholipid Syndrome in Pregnancy: New and Old Pathogenetic Mechanisms

D’Ippolito

Barbaro

Paciullo

et al. 2023

IJMS

View full text Add to dashboard Cite

The antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized, according to the Sydney criteria, by the persistent presence of autoantibodies directed against phospholipid-binding proteins associated with thrombosis and/or obstetrical complications. The most frequent complications in obstetric antiphospholipid syndrome are recurrent pregnancy losses and premature birth due to placental insufficiency or severe preeclampsia. In recent years, vascular APS (VAPS) and obstetric APS (OAPS) have been described as two different clinical entities. In VAPS, antiphospholipid antibodies (aPL) interfere with the mechanisms of coagulation cascade and the ‘two hit hypothesis’ has been suggested to explain why aPL positivity does not always lead to thrombosis. OAPS seems to involve additional mechanisms, such as the direct action of anti-β2 glycoprotein-I on trophoblast cells that can lead to a direct placental functional damage. Furthermore, new actors seem to play a role in the pathogenesis of OAPS, including extracellular vesicles, micro-RNAs and the release of neutrophil extracellular traps. The aim of this review is to investigate the state-of-the-art antiphospholipid syndrome pathogenesis in pregnancy, in order to provide a comprehensive overview of both old and new pathogenetic mechanisms involved in this complex disease.

show abstract

“…The value of IgA aβ2GPI in APS diagnosis is still controversial. Some studies support their clinical relevance in APS 4–6 while others failed to demonstrate an added value of this isotype 7,8 . Otherwise, aβ2GPI‐IgA have been linked to atherosclerotic disease, 9 chronic renal disease, 10 early mortality after heart transplantation 11 and cardiovascular mortality in hemodialysis patients 12 .…”

Section: Introductionmentioning

confidence: 99%

Anticardiolipin and anti‐beta 2‐glycoprotein I antibodies in patients with unexplained articular manifestations

Melayah

Ghozzi

Ghedira

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Objective To determine the frequency of antiphospholipid antibodies (aPL) in patients with unexplained articular manifestations. Material and Methods Three hundred thirteen patients suffering from arthritis or arthralgia without evident cause and 266 healthy blood donors (HBD) were included in the study. Anticardiolipin antibodies (aCL) and anti‐beta 2‐glycoprotein I antibodies (aβ2GPI) were measured by ELISA. Result Out of the 313 patients, 250 were females and 63 were males. The mean age of patients was 49 ± 14 years (17–87 years). One hundred eleven patients have arthralgia and 202 have arthritis. The frequency of aCL and/or aβ2GPI (24.9%) was significantly higher in patients than in HBD (10.9%). The frequency of aβ2GPI was 23.6% in patients and 9.4% in the control group (p < 10−3). aβ2GPI‐IgA was significantly more frequent in patients than in the control group (20.4% vs. 7.5%, p < 10−3). aβ2GPI was most commonly observed than aCL in patients (23.6% vs. 6.4%, p < 10−6). IgA isotype of aβ2GPI was the most frequent in 20.4% of patients while IgG and IgM were detected in 5.4% and 2.9% respectively. Conclusion This study showed that aPL were common in patients with articular manifestations and were mainly directed against β2GPI. The role of these antibodies remains to be specified.

show abstract

IgA Antiphospholipid Antibodies in Antiphospholipid Syndrome and Systemic Lupus Erythematosus

Cited by 11 publications

References 27 publications

Research trends and frontiers on antiphospholipid syndrome: A 10-year bibliometric analysis (2012–2021)

Research trends and frontiers on antiphospholipid syndrome: A 10-year bibliometric analysis (2012–2021)

Antiphospholipid Syndrome in Pregnancy: New and Old Pathogenetic Mechanisms

Anticardiolipin and anti‐beta 2‐glycoprotein I antibodies in patients with unexplained articular manifestations

Contact Info

Product

Resources

About